through advanced stem cell
AMNICELL leverages technology in the exciting new field of regenerative medicine by being the
first company to use amniotic fluid stem cells to improve health and wellness, including COVID-19 and other serious lung disease
stem cell technology
AMNICELL is the first company to recognize the unique capability of human amniotic
fluid as an abundant source for novel stem cell products
AMNICELL was formed in 2018, after 10 years of dedicated scientific research. We recognized the unique qualities of human amniotic fluid. This led us to develop novel amniotic fluid stem cell technologies for areas of unmet medical need and wellness, such as COVID 19 lung disease. There is a need for new improved stem cell treatment options and we have developed specific technology for collection, processing, storage and products. We are exploring new applications for stem cells and amniotic fluid. Our initial commitments are a transformative product for COVID 19 lung disease, non-healing wounds and innovative cosmeceuticals for hair and skin.
Stem cell therapy
AMNICELL is different. Our approach uses a natural non-controversial abundant source of human stem cells. We are the first to collect stem cells from the full term amniotic fluid without interfering with the mother or child. Stem cells are the building blocks and renewal source for all cells in the body. They are pluripotent, meaning they can be turned into any kind of cell and can renew and maintain various tissues to provide regenerative treatments. Until recently, scientists worked with embryonic stem cells and virally transduced or chemically induced adult stem cells. AMNICELL stem cells are different and unique.
Amniotic fluid stem cells
At AMNICELL, we have a technique for collecting amniotic fluid and stem cells at the time of cesarean birth. Because they are natural stem cells, we collect and store them unchanged for clinical use, such as for the treatment of COVID-19 lung disease, non-healing wounds, as well as using them in hair and skin care products. The amniotic fluid contains chemical messengers and hormones that restore tissues and stimulate growth. Amniotic fluid provides millions of pluripotent human stem cells that have the ability to replicate rapidly. Similar to other stem cells, these cells can differentiate into several different cell lineages and provide clinical benefit. Unlike other stem cells, no manipulation, prolonged culture or embryonic source is used.
At AMNICELL, our research focus is on the development of amniotic fluid and stem cells for use in various therapeutic areas of unmet medical need, such as COVID-19 and other serious lung disease, non-healing wounds, as well as hair and skin products. Our initial development program is focusing on the treatment of serious COVID-19 lung disease as well as the treatment of chronic non-healing wounds. Other areas for product development are skin care products and hair growth. Also under investigation are treatments for end-stage lung disease, diabetic foot ulcers and diabetes.
The research and development, as well as the growth of AMNICELL, will initially be funded by a select group of independent investors and grants. The company plans to be self-funded within 3-5 years of product launch. Should you be interested in discussing investment opportunities contact us.
You can reach us on:
Regenerative medicine and amniotic fluid stem cell therapy
Regenerative medicine is the next great step in modern healthcare, and will allow for the introduction of novel and innovative treatment options across important areas of medical need.
AMNICELL is the first company to use amniotic fluid derived stem cells for clinical use. Our cells are not from embryos or reprogrammed in order to become stem cells. Unlike other types of stem cells, amniotic fluid stem cells are uniquely suited for regenerative medicine for a number of reasons:
- sourced from a natural human fluid discarded at birth, not from embryos
- abundant and replicate rapidly
- naturally ready to be used
- retain their vitality after long-term cryo-storage
- not associated with any increased risk for tumors
- improve tolerance of transplants by suppressing immune reactions
- shown to reduce inflammation and scarring
At AMNICELL, we will explore these characteristics to develop transformative treatments for serious medical conditions such as COVID-19 lung disease, non-healing wounds, and innovative therapies for hair and skin care. After 10 years of scientific research we have the technology to collect, store, preserve and package these cells for clinical use. Our initial focus is on the treatment of serious COVID-19 lung disease. We will also leverage our technology for novel advanced treatment of chronic non-healing wounds, which affect 6.5 million people in the US annually. A strong focus is also on novel hair and skin care treatments using the restorative power of amniotic fluid.